On the other hand, Ortega and co-workers recently found plasma and urinary levels of calprotectin associated with insulin resistance and low-grade inflammation independent of obesity in T2DM patients, which lead to the hypothesis that calprotectin may be a biomarker of decreased insulin sensitivity beyond a common trait of obesity and inflammation [27]. This evidence concerns the gene INS and obesity due to melanocortin 4 receptor deficiency.